Jaguar Health, Inc. (JAGX) AI Stock Analysis

Jaguar Health, Inc. is a pharmaceutical company that develops prescription medications for human and animal gastrointestinal disorders, particularly chronic and debilitating diarrhea. Operating via Human Health and Animal Health segments, the company markets Mytesi for symptomatic relief of noninfectious diarrhea in adults living with HIV/AIDS on antiretroviral therapy. It is also advancing Crofelemer for cancer therapy-related diarrhea, orphan pediatric indications, inflammatory bowel diseases, short bowel syndrome, and irritable bowel syndrome. Additionally, its Animal Health segment develops Canalevia for chemotherapy-induced and exercise-induced diarrhea in dogs, alongside lechlemer for cholera.

From FY2021 to FY2025, Jaguar Health showed fluctuating top-line results, starting at $4.3M in FY2021 before increasing 175.8% to $12.0M in FY2022. Revenue reached $9.8M in FY2023 and $11.7M in FY2024, followed by a 1.5% decrease to $11.5M in FY2025, reflecting a 5-year CAGR of 4.2% from FY2020. Annual net losses remained elevated, reporting -$52.6M in FY2021, -$47.5M in FY2022, -$41.3M in FY2023, -$38.5M in FY2024, and -$53.4M in FY2025. In the latest quarter ended June 30, 2026, quarterly revenue fell 58.9% year-over-year, while trailing twelve-month revenue totaled $27.8M with a net profit margin of -130.8%.

As of June 30, 2026, Jaguar Health held $6.6M in cash and short-term investments alongside total debt of $16.7M, resulting in net debt of $10.1M. Shareholders' equity was $6.6M against total assets of $34.2M, with a current ratio of 0.69 and a debt-to-equity ratio of 2.52. During FY2025, operating cash flow turned positive to $5.8M, matching free cash flow of $5.8M. For cash use in FY2025, the company deployed $25,000 toward capital expenditures and spent $31.1M on share buybacks.

Jaguar Health carries a market cap of $6.9M and an enterprise value of $19.1M. The stock trades at a price-to-sales ratio of 0.2x and an EV-to-revenue ratio of 0.7x, both below the median of its US-listed Healthcare peers, which trades at a price-to-sales multiple of 4.1x. Its forward P/E stands at 200.0x compared to the peer median of 17.3x. Over the past year, JAGX fell 99.7%, lagging the S&P 500 (SPY) gain of 16.8%, and is down 100.0% over a 5-year span.

Covering Wall Street research sets a mean price target of $262.50, representing an implied premium of 7346.8% over the last close of $3.52. For the current fiscal year ending December 31, 2026, estimates project an EPS of -$4.20 on $0 in revenue. For next fiscal year, one analyst forecasts revenue of $14.1M and an EPS of -$9.45. Over the last four quarters, Jaguar Health exceeded EPS estimates once. The company's next earnings date is scheduled for November 13, 2026.

This page is an AI-written research summary of Jaguar Health, Inc. (JAGX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: JAGX income statement, JAGX balance sheet, JAGX key metrics, JAGX analyst forecast, JAGX chart. See the JAGX stock overview for the latest quote and news.